MX341492B - Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona. - Google Patents

Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.

Info

Publication number
MX341492B
MX341492B MX2014004678A MX2014004678A MX341492B MX 341492 B MX341492 B MX 341492B MX 2014004678 A MX2014004678 A MX 2014004678A MX 2014004678 A MX2014004678 A MX 2014004678A MX 341492 B MX341492 B MX 341492B
Authority
MX
Mexico
Prior art keywords
solid forms
methanone
thiomorpholinyl
dioxo
isoxazolyl
Prior art date
Application number
MX2014004678A
Other languages
English (en)
Other versions
MX2014004678A (es
Inventor
Schwitter Urs
Dott Pascal
Thomas Andrew
Grassmann Olaf
Kammerer Michael
Manns Joachim
Wyttenbach Nicole
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014004678A publication Critical patent/MX2014004678A/es
Publication of MX341492B publication Critical patent/MX341492B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a nuevas formas sólidas del compuesto de la fórmula (I) (ver Fórmula) así como a solvatos, complejos de inclusión con otros compuestos idóneos, a procesos de obtención, a composiciones farmacéuticas que contienen estas formas sólidas y a su utilización como medicamentos.
MX2014004678A 2011-10-20 2012-10-17 Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona. MX341492B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11185993 2011-10-20
PCT/EP2012/070522 WO2013057124A1 (en) 2011-10-20 2012-10-17 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone

Publications (2)

Publication Number Publication Date
MX2014004678A MX2014004678A (es) 2014-05-28
MX341492B true MX341492B (es) 2016-08-23

Family

ID=47019027

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004678A MX341492B (es) 2011-10-20 2012-10-17 Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.

Country Status (20)

Country Link
US (2) US8785435B2 (es)
EP (1) EP2768821B1 (es)
JP (1) JP5918856B2 (es)
KR (1) KR20140079503A (es)
CN (1) CN103889971B (es)
AR (1) AR088359A1 (es)
AU (1) AU2012318294B2 (es)
BR (1) BR112014009288A8 (es)
CA (1) CA2850441A1 (es)
DK (1) DK2768821T3 (es)
ES (1) ES2606547T3 (es)
HK (1) HK1193611A1 (es)
HU (1) HUE030298T2 (es)
IL (1) IL231532A0 (es)
MX (1) MX341492B (es)
PL (1) PL2768821T3 (es)
RU (1) RU2618524C2 (es)
SG (1) SG11201401591WA (es)
SI (1) SI2768821T1 (es)
WO (1) WO2013057124A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EP3675845A4 (en) 2017-08-28 2021-05-05 University of Maryland, Baltimore NEW GAMMA AMINOBUTIC ACID TYPE A RECEPTOR MODULATORS FOR EMOTIONAL DISORDERS
CA3102101A1 (en) 2018-06-13 2019-12-19 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as gaba a alpha5 pam

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE352505C (de) 1918-03-01 1922-04-27 Metallbank Verfahren zur Verarbeitung von Salmiakschlacken
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
AU5467699A (en) 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
ES2195943T3 (es) 1999-11-12 2003-12-16 Neurogen Corp Compuestos heteroaromaticos biciclicos y triciclicos.
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
EA005934B1 (ru) 2001-07-05 2005-08-25 Х. Лундбекк А/С Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2002353844A1 (en) 2001-11-20 2003-06-10 Eli Lilly And Company Beta 3 adrenergic agonists
GB0128160D0 (en) 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1745027A4 (en) 2004-05-14 2009-06-03 Irm Llc COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
DE602005007350D1 (de) 2004-06-01 2008-07-17 Hoffmann La Roche Pyridin-4-yl-ethynylimidazole und -pyrazole als antagonisten des mglu5-rezeptors
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ES2315912T3 (es) 2004-10-01 2009-04-01 F. Hoffmann-La Roche Ag Derivados de eter sustituido por hexafluorisopropanol.
EP1812427A4 (en) 2004-10-15 2009-10-14 Scripps Research Inst FATTY ACID AMIDE HYDROLASE OXADIAZOLE KETONE INHIBITORS
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006095822A1 (ja) 2005-03-11 2006-09-14 Ono Pharmaceutical Co., Ltd. スルホンアミド化合物およびその医薬
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE484416T1 (de) 2005-07-20 2010-10-15 Prospective Concepts Ag Pneumatisch verstellbare seitenwangen für fahrzeugsitze
BRPI0616184A2 (pt) 2005-09-19 2011-06-07 Hoffmann La Roche derivados de isoxazolo como agonistas inversos gaba a alfa 5, processo para a preparação dos mesmos, medicamento e uso dos referidos derivados
JP2009511533A (ja) 2005-10-11 2009-03-19 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾール誘導体
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
CN101316838B (zh) * 2005-11-30 2013-01-30 霍夫曼-拉罗奇有限公司 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
WO2007071476A1 (en) * 2005-12-20 2007-06-28 International Business Machines Corporation Method, system and computer program for distributing software products based on an e-mail service
CN101374834B (zh) 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
AU2007267183B2 (en) 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
JP2010524953A (ja) 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
EP2229383B1 (en) 2007-12-04 2017-01-18 F. Hoffmann-La Roche AG Isoxazolo-pyrazine derivatives
DK2767536T3 (en) 2007-12-04 2015-10-19 Hoffmann La Roche Isoxazolo-pyridine derivatives

Also Published As

Publication number Publication date
AU2012318294B2 (en) 2015-10-01
BR112014009288A2 (pt) 2017-06-13
JP2014530832A (ja) 2014-11-20
SI2768821T1 (sl) 2017-01-31
AR088359A1 (es) 2014-05-28
IL231532A0 (en) 2014-04-30
AU2012318294A1 (en) 2013-05-09
BR112014009288A8 (pt) 2020-04-22
MX2014004678A (es) 2014-05-28
DK2768821T3 (en) 2017-01-23
ES2606547T3 (es) 2017-03-24
PL2768821T3 (pl) 2017-05-31
JP5918856B2 (ja) 2016-05-18
CN103889971A (zh) 2014-06-25
EP2768821B1 (en) 2016-11-16
RU2618524C2 (ru) 2017-05-04
CN103889971B (zh) 2016-08-31
HUE030298T2 (en) 2017-04-28
SG11201401591WA (en) 2014-05-29
RU2014118968A (ru) 2015-11-27
WO2013057124A1 (en) 2013-04-25
NZ622215A (en) 2016-06-24
US8785435B2 (en) 2014-07-22
HK1193611A1 (zh) 2014-09-26
US20130172329A1 (en) 2013-07-04
EP2768821A1 (en) 2014-08-27
US20140329806A1 (en) 2014-11-06
CA2850441A1 (en) 2013-04-25
KR20140079503A (ko) 2014-06-26
US8975397B2 (en) 2015-03-10

Similar Documents

Publication Publication Date Title
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
PH12017500755A1 (en) 2 substituted cephem compounds
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
MD4664C9 (ro) Lactame aril şi heteroaril condensate
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
GEP201606555B (en) Compounds and compositions for modulating egfr activity
PH12015501609A1 (en) Phenicol antibacterials
MD20140136A2 (ro) Inhibitori ai virusului hepatic C
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
IN2014CN04530A (es)
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
MX2012013274A (es) Novedosos derivados de la pirimidina.
MY169267A (en) New aryl-quinoline derivatives
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
MX2012006909A (es) LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
TW200738627A (en) Trialkylsilyl-indoles
TN2016000003A1 (en) New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
MY152018A (en) Indole derivatives as anticancer agents
MX2014004678A (es) Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.

Legal Events

Date Code Title Description
FG Grant or registration